The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis
- PMID: 35120852
- DOI: 10.1016/j.clml.2022.01.003
The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis
Keywords: JAKARTA; JAKARTA2; Metabolic effects; Ruxolitinib; Weight gain.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources